MarketCapExport financials
West Pharmaceutical Services (WST)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
West Pharmaceutical Services Cash Flow 2025-2007 | WST
Brief cash flow overview of West Pharmaceutical Services
The comparison covers five available annual reports between 2021 and 2025.
Operating cash flow increased from $584 million to $754.8 million, gaining +29.2%. CAGR near 6.6% reflects steady momentum.
Operating cash flow was positive in all five observations, adding repeatability to the cash profile.
Operating cash flow covered cumulative profit by 1.24x, providing strong cash confirmation.
At the end, 24.6% of revenue converted into operating cash flow versus 20.6% previously.
What the cash flows show
West Pharmaceutical Services's cash position is positive. The business can fund investment and obligations mainly from internal sources.
Annual Cash Flow West Pharmaceutical Services
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
755 M | 653 M | 776 M | 724 M | 584 M | 472 M | 367 M | 289 M | 263 M | 219 M | 212 M | 183 M | 220 M | 187 M | 131 M | 138 M | 138 M | 135 M | - |
Depreciation & Amortization |
171 M | 155 M | 137 M | 121 M | 122 M | 109 M | 103 M | 104 M | 96.7 M | 90.7 M | 89.9 M | 90 M | 85.2 M | 76.9 M | 75.7 M | 73.2 M | 68.1 M | 56.1 M | - |
Accounts Payables |
254 M | 239 M | 242 M | 215 M | 232 M | 213 M | 157 M | 130 M | 138 M | 122 M | 120 M | 103 M | 108 M | 103 M | 89.8 M | 63.2 M | 68.4 M | - | - |
Accounts Receivables |
574 M | 552 M | 512 M | 507 M | 489 M | 385 M | 319 M | 288 M | 253 M | 200 M | 181 M | 179 M | 186 M | 175 M | 147 M | 126 M | 139 M | - | - |
Total Inventories |
444 M | 377 M | 435 M | 415 M | 378 M | 321 M | 236 M | 214 M | 215 M | 199 M | 181 M | 182 M | 177 M | 162 M | 152 M | 147 M | 129 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow West Pharmaceutical Services
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 124 M | 89.9 M | 251 M | 197 M | 177 M | 129 M | 190 M | 180 M | 165 M | 118 M | 239 M | 230 M | 169 M | 138 M | 231 M | 169 M | 173 M | 151 M | 161 M | 190 M | 144 M | 88.7 M | 149 M | 119 M | 148 M | 57.1 M | 106 M | 108 M | 105 M | 47.6 M | 73.2 M | 88.4 M | 82 M | 45 M | 81.5 M | 75.8 M | 85.3 M | 20.7 M | 71.8 M | 68.4 M | 76.2 M | 3 M | 68 M | 68.8 M | 77.5 M | -1.9 M | 46 M | 63.9 M | 64.2 M | 8.8 M | 68.8 M | 53.3 M | 79.5 M | 18.9 M | 69.8 M | 51.6 M | 52.2 M | 13.8 M | 41.8 M | 39.7 M | 39.7 M | 9.5 M | 47.2 M | 48 M | 43.1 M |
Depreciation & Amortization |
45.9 M | 46.2 M | 44.6 M | -121 M | 43 M | 41.4 M | 39.1 M | -110 M | 40.2 M | 38.9 M | 34.7 M | -95.5 M | 34.8 M | 33.6 M | 30.7 M | -83.1 M | 28.9 M | 57.7 M | 200 K | -79.2 M | 28.9 M | 55.5 M | 200 K | -72.9 M | 52.2 M | 200 K | 24.9 M | -71.2 M | 24.4 M | 25.3 M | 24.9 M | -73.4 M | 25.5 M | 24.9 M | 25.7 M | -67.5 M | 24.5 M | 22.8 M | 22.6 M | -63.3 M | 22.2 M | 22.1 M | 21.6 M | -60.1 M | 21.5 M | 21.1 M | 21 M | -59 M | 21.3 M | 22 M | 20.6 M | -56 M | 20.8 M | 19.7 M | 19.4 M | -49.7 M | 18.4 M | 17.7 M | 17.5 M | -49.6 M | 17.4 M | 18.2 M | 18.3 M | - | 17.2 M | 33.2 M |
Accounts Payables |
249 M | 253 M | 252 M | 254 M | 256 M | 239 M | 228 M | 239 M | 224 M | 212 M | 240 M | 242 M | 220 M | 218 M | 234 M | 215 M | 189 M | 220 M | 248 M | 232 M | 208 M | 205 M | 204 M | 213 M | 180 M | 162 M | 158 M | 157 M | 145 M | 152 M | 138 M | 130 M | 125 M | 126 M | 128 M | 138 M | 122 M | 131 M | 106 M | 122 M | 99 M | 107 M | 97.5 M | 120 M | 93.6 M | 91.4 M | 88.5 M | 103 M | 91.4 M | 94.5 M | 98.4 M | 108 M | 86.3 M | 88.4 M | 91.6 M | 103 M | 81.3 M | 85.6 M | 82.7 M | 89.8 M | 71.7 M | 73.4 M | 66.2 M | 63.2 M | 56.3 M | 61.4 M |
Accounts Receivables |
748 M | 712 M | 686 M | 574 M | 625 M | 582 M | 544 M | 552 M | 524 M | 479 M | 524 M | 512 M | 519 M | 534 M | 513 M | 507 M | 485 M | 528 M | 499 M | 489 M | 476 M | 480 M | 466 M | 385 M | 373 M | 341 M | 333 M | 319 M | 316 M | 331 M | 318 M | 288 M | 303 M | 297 M | 290 M | 253 M | 252 M | 242 M | 225 M | 200 M | 210 M | 219 M | 210 M | 181 M | 195 M | 199 M | 190 M | 179 M | 196 M | 210 M | 209 M | 186 M | 198 M | 195 M | 189 M | 175 M | 183 M | 185 M | 176 M | 147 M | 153 M | 166 M | 161 M | 126 M | 143 M | 146 M |
Total Inventories |
465 M | 447 M | 453 M | 444 M | 438 M | 421 M | 389 M | 377 M | 401 M | 419 M | 430 M | 435 M | 432 M | 449 M | 447 M | 415 M | 413 M | 412 M | 416 M | 378 M | 354 M | 345 M | 310 M | 321 M | 295 M | 275 M | 251 M | 236 M | 230 M | 232 M | 226 M | 214 M | 207 M | 208 M | 216 M | 215 M | 216 M | 211 M | 212 M | 199 M | 201 M | 198 M | 194 M | 181 M | 188 M | 187 M | 183 M | 182 M | 186 M | 188 M | 188 M | 177 M | 177 M | 176 M | 174 M | 162 M | 166 M | 159 M | 158 M | 152 M | 156 M | 161 M | 157 M | 147 M | 148 M | 143 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company West Pharmaceutical Services, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Alcon
ALC
|
$ 74.11 | -1.37 % | $ 36.6 B |  Schweiz |
 |
Baxter International
BAX
|
$ 26.43 | 0.06 % | $ 13.6 B | USA |
 |
The Cooper Companies
COO
|
$ 63.6 | -0.52 % | $ 12.7 B | USA |
 |
electroCore
ECOR
|
$ 7.68 | 6.96 % | $ 65.1 M | USA |
 |
ResMed
RMD
|
$ 234.15 | -0.67 % | $ 34.1 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.55 | -1.5 % | $ 16.5 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 24.25 | -1.22 % | $ 1.2 B | USA |
 |
STERIS plc
STE
|
$ 257.0 | 0.02 % | $ 25.2 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 155.37 | 0.27 % | $ 6.93 B | USA |
 |
Utah Medical Products
UTMD
|
$ 72.86 | -0.01 % | $ 236 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 15.24 | 3.81 % | $ 315 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.77 | 2.36 % | $ 1.95 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 86.01 | -3.07 % | $ 2.75 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 449.99 | -2.3 % | $ 161 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.17 | -1.86 % | $ 146 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 213.55 | -1.21 % | $ 61.4 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
AtriCure
ATRC
|
$ 56.21 | -2.74 % | $ 2.68 B | USA |
 |
AngioDynamics
ANGO
|
$ 12.07 | -0.45 % | $ 501 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 236.28 | -1.03 % | $ 13.5 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 9.39 | 3.3 % | $ 417 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.41 | -3.54 % | $ 251 M | USA |
 |
Microbot Medical
MBOT
|
$ 1.06 | -4.09 % | $ 48.5 M |  Israel |
 |
Haemonetics Corporation
HAE
|
$ 122.34 | 3.49 % | $ 5.77 B | USA |
 |
ICU Medical
ICUI
|
$ 182.28 | 1.86 % | $ 4.49 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.3 | -0.36 % | $ 24.6 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 87.87 | -0.62 % | $ 5.2 B | USA |
 |
Nephros
NEPH
|
$ 3.13 | 4.33 % | $ 33.2 M | USA |
 |
Pro-Dex
PDEX
|
$ 70.6 | 0.43 % | $ 228 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.87 | -0.19 % | $ 4.35 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 78.94 | -2.74 % | $ 1.79 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 55.1 | -5.28 % | $ 3.71 B | USA |
 |
Repligen Corporation
RGEN
|
$ 174.04 | -2.74 % | $ 9.79 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Stereotaxis
STXS
|
$ 1.05 | -7.89 % | $ 95.5 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |